A digital health platform for assisting in diagnosing and monitoring disease progression of COVID-19: An adjuvant approach for augmenting the anti-viral response and reducing the immune-mediated target organ damage (Preprint)

2020 ◽  
Author(s):  
Yaron Ilan ◽  
Yuval Isahy ◽  
Assaf Potruch ◽  
Asaf Schwartz ◽  
Marc Berg ◽  
...  
Keyword(s):  
Health Care Providers ◽  
Digital Health ◽  
Target Organ Damage ◽  
Relevant Literature ◽  
Organ Damage ◽  
Target Organ ◽  
Care Providers ◽  
Viral Response ◽  
Monitoring Tools ◽  
Immune Mediated

BACKGROUND The outbreak of a coronavirus disease in 2019 (COVID-19) which is associated with respiratory-related illness and high mortality presents a major worldwide need. Problems of information availability to health care providers; difficulties in diagnosis and disease prognosis; and a lack of monitoring tools are some of the obstacles faced by the clinical community. Most importantly, the lack of valid therapies makes the pandemic a devastating universal problem. Current information points to a concept of dysregulation of the immune system which is unable to mount an effective anti-viral response, and on the other hand induces an uncontrolled immune-mediated response manifesting as ARDS, myocarditis and hepatitis.   OBJECTIVE In the present paper we describe a novel platform for providing information to physicians, and assisting in diagnosis and monitoring of patients with COVID-19. METHODS Review of the relevant literature publications RESULTS An adjuvant approach is presented, using compounds that can boost a beneficial anti-viral immune response while reducing the immune-mediated target organ damage associated with the virus. CONCLUSIONS Ensuring a prolonged beneficial effect is performed by implementing algorithm-based individualized variability measures into the treatment regimen.

Engagement patterns of users and providers: a study of messaging on app usage in a smartphone app for the treatment of eating disorders (Preprint)

2020 ◽  
Author(s):  
Jane Kim ◽  
Jisung Park ◽  
Jenna Tregarthen
Keyword(s):  
Eating Disorders ◽  
Health Care Providers ◽  
Digital Health ◽  
Communication Styles ◽  
Care Providers ◽  
Digital Tool ◽  
Self Monitoring ◽  
Multiple Phenotypes ◽  
Monitoring Tools ◽  
Level Data

BACKGROUND By offering the ability to immediately communicate with health care providers, digital health apps may significantly bolster the therapeutic relationship. Increasing opportunities of engagement with a digital tool, self-monitoring tools show confer promise in allowing patients to go through periods in between in-clinic visits. Little is known however, regarding the usage of the apps and whether communication between providers and app users in fact encourages usage. OBJECTIVE The objective of this study was to investigate the users of an app for eating disorders and summarize the characteristics of usage, characteristics of communication (i.e. messages sent and received), and assess whether the degree of communication and the degree of app usage (of the main features of the app precluding provider contact) were related. METHODS Users of an app for eating disorders (Tregarthen et al) consented for their de-identified, aggregate level data to be utilized for research. Records of five hundred users were randomly sampled from May 2017 to July 2017. All users in the sampled cohort were linked to a clinician. Raw data included 97,732 observations of meal logs submitted via app across 500 individuals. RESULTS Our data demonstrated a high degree of variability across users in their engagement patterns of the app. Receiving more messages on average had a greater effect on usage than sending messages, implying that being checked in on by clinicians may encourage users to engage more with their app. Data also demonstrated that there were multiple phenotypes in terms of preferences regarding communication – while a portion of users seemed to benefit, a large minority did not demonstrate a change in usage based on the frequency of communication. CONCLUSIONS Understanding usage phenotypes can be instrumental in helping clinician and apps understand who their user is. This work demonstrates that variability among the user population in terms of usage and communication styles, as well as usage and behavior. This information can ultimately be leveraged for guiding effective treatment delivery.

Inflammation and Target Organ Damage in Hypertension With or Without Metabolic Syndrome

2005 ◽  
Vol 12 (3) ◽  
pp. 175
Author(s):  
A. Ferrucci ◽  
S. Sciarretta ◽  
V. Venturelli ◽  
G. M. Ciavarella ◽  
P. De Paolis ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ

Nocturnal Hypertension, Nondipping Phenomenon and Target Organ Damage in Obstructive Sleep Apnea Patients - The Bad and the Worse

2015 ◽  
Vol 10 (3) ◽  
pp. 182-188 ◽  
Author(s):  
Radostina Vlaeva Cherneva ◽  
Ognian Borisov Georgiev ◽  
Daniela Stoichkova Petrova ◽  
Emil Ivanov Manov ◽  
Dinko Georgiev Valev ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Target Organ ◽  
Nocturnal Hypertension ◽  
Obstructive Sleep

scholarly journals Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Jingsi Zhang ◽  
Lina Yang ◽  
Yanchun Ding
Keyword(s):  
Ventricular Hypertrophy ◽  
Target Organ Damage ◽  
Organ Damage ◽  
Left Ventricular ◽  
Target Organ ◽  
Dependent Manner ◽  
Concentration Dependent Manner ◽  
Hypertensive Patients ◽  
Inflammatory Status ◽  
Tnf Α

Abstract Background Circulating monocytes and tissue macrophages play complex roles in the pathogenesis of hypertension and the resulting target organ damage. In this study, we observed alterations in the monocyte phenotype and inflammatory state of hypertensive patients with left ventricular hypertrophy (LVH) and studied the effects of irbesartan in these patients. This study might reveal a novel mechanism by which irbesartan alleviates LVH, and it could provide new targets for the prevention and treatment of hypertensive target organ damage. Methods CD163 and CD206 expression on monocytes and IL-10 and TNF-α levels in the serum of hypertensive patients with or without LVH and of healthy volunteers were detected. Furthermore, we treated monocytes from the LVH group with different concentrations of irbesartan, and then, CD163, CD206, IL-10 and TNF-α expression was detected. Results We found, for the first time, that the expression of CD163, CD206 and IL-10 in the LVH group was lower than that in the non-LVH group and healthy control group, but the TNF-α level in the LVH group was significantly higher. Irbesartan upregulated the expression of CD163 and CD206 in hypertensive patients with LVH in a concentration-dependent manner. Irbesartan also increased the expression of IL-10 and inhibited the expression of TNF-α in monocyte culture supernatants in a concentration-dependent manner. Conclusions Our data suggest that inflammation was activated in hypertensive patients with LVH and that the monocyte phenotype was mainly proinflammatory. The expression of proinflammatory factors increased while the expression of anti-inflammatory factors decreased. Irbesartan could alter the monocyte phenotype and inflammatory status in hypertensive patients with LVH. This previously unknown mechanism may explain how irbesartan alleviates LVH. Trail registration The study protocols were approved by the Ethical Committee of the Second Affiliated Hospital of Dalian Medical University. Each patient signed the informed consent form.

Sign in / Sign up

Export Citation Format

Share Document